Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA- nonidentical unrelated marrow grafts

Blood

Volumn 91, Issue 7, 1998, Pages 2581-2587

  Yu, Cong ^a   Seidel, Kristy ^b   Nash, Richard A ^b   Deeg, H Joachim ^b   Sandmaier, Brenda M ^b   Barsoukov, Alexander ^b   Santos, Erlinda ^b   Storb, Rainer ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032055163     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.7.2581     Document Type: Article

References (30)

1. Storb R, Deeg HJ, Raff R, Schuening F, Yu C, Sandmaier BM, Graham T: Prevention of graft-versus-host disease: Studies in a canine model, in Sackstein R, Janssen WE, Elfenbein GJ (eds): Bone Marrow Transplantation: Foundations for the 21st Century. New York, NY, Annals of the New York Academy of Sciences, 1995, p 149
2. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, Graham TC, Thomas ED: Cyclosporin A and methotrexate in canine marrow transplantation: Engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 34:30, 1982
3. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, Van Der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation 56:800, 1993
4. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
5. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986
6. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, Van Der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood 85:3746, 1995
7. Sollinger HW: From mice to man: The preclinical history of mycophenolate mofetil (Review). Clin Transplant 10:85, 1996
8. Halloran PF: Molecular mechanisms of new immunosuppressants (Review). Clin Transplant 10:118, 1996
9. Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 23:10, 1991
10. Lee HJ, Pawlak K, Nguyen BT, Robins RK, Sadee W: Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 45:5512, 1985
11. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23:15, 1991
12. Coulombe M, Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty K: Tolerance induction in adult animals: Comparison of RS-61443 and anti-CD4 treatment. Transplant Proc 23:31, 1991
13. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC: RS-61443-a new, potent immunosuppressive agent. Transplantation 51:27, 1991
14. Sollinger HW: Update on preclinical and clinical experience with mycophenolate mofetil (Review). Transplant Proc 28:24, 1996
15. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA: Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 62:876, 1996
16. Wagner JL, Burnett RC, Works JD, Storb R: Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 48:554, 1996
17. Ladiges WC, Storb R, Graham T, Thomas ED: Experimental techniques used to study the immune system of dogs and other large animals, in Gay WI, Heavener JE (eds): Methods of Animal Experimentation. New York, NY, Academic, 1989, p 103
18. Storb R, Deeg HJ: Failure of allogeneic canine marrow grafts after total body irradiation: Allogeneic "resistance" vs transfusion induced sensitization. Transplantation 42:571, 1986
19. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 58:701, 1994
20. Ochs HD, Storb R, Thomas ED, Kolb H-J, Graham TC, Mickelson E, Parr M, Rudolph RH: Immunologic reactivity in canine marrow graft recipients. J Immunol 113:1039, 1974
21. Tan PHS, Santos EB, Rossbach HC, Sandmaier BM: Enhancement of natural killer activity by an antibody to CD44. J Immunol 150:812, 1993
22. Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, Yu C, Schuening FG, Deeg HJ, Graham T: Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 87:3508, 1996
23. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, Leisenring W, Shulman H: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048, 1997
24. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC, Seidel K, Burnett R, Wagner JL, Shulman H, Sandmaier BM: DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 86:4376, 1995
25. Wagner JL, Storb R: Preclinical large animal models for hematopoietic stem cell transplantation. Curr Opin Hematol 3:410, 1996
26. Yu C, Storb R, Braude I, Deeg HJ, Schuening FG, Huss R, Graham TC: Corticotropin releasing factor with or without methotrexate for prevention of graft-versus-host disease in DLA-nonidentical unrelated canine marrow grafts. Transplantation 60:384, 1995
27. Storb R, Kolb HJ, Deeg HJ, Weiden PL, Appelbaum F, Graham TC, Thomas ED: Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant 1:167, 1986
28. Benhaim P, Anthony JP, Ferreira L, Borsanyi JP, Mathes SJ: Use of combination of low-dose cyclosporine and RS-61443 in a rat hindlimb model of composite tissue allotransplantation. Transplantation 61:527, 1996
29. Raff RF, Loughran TP Jr, Deeg HJ, Aprile JA, Graham TC, Sale GE, Storb R: Role of radiation-resistant large granular lymphocytes in the rejection of unrelated DLA-nonidentical marrow grafts in dogs. Transplant Proc 19:2718, 1987
30. Raff RF, Sandmaier BM, Graham T, Loughran TP Jr, Pettinger M, Storb R: "Resistance" to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 22:893, 1994